| Objective:To investigate the difference of serum pigment epithelium-derived factor(PEDF) among Type 2 diabetes patients before and after use of dipeptidyl peptidase-4 (DPP-4) inhibitors Linaglipin for treatment, and to explore the correlation of serum PEDF with Lipids^ body mass index (BMI) and HbA1c.Methods:39 patients with newly diagnosed type 2 diabetes was selected as Linaglipin treatment group,30 healthy individuals as a control group. Baseline weight, waist circumference, body mass index, fasting plasma glucose, glycosylated hemoglobin,total cholesterol,triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, glutamic-pyruvic transaminase, glutamic oxaloacetic transaminase and PEDF quantified by ELASA were determined both in the diabetic and control subject. Treatment group were treated with oral Linaglipin 5mg/d for six month, serum PEDF and clinical parameters were determined in the diabetic group by 6 months treatment.Results:(1) Type 2 diabetes group of body weight、waist circumference、body mass index、fasting plasma glucose、HbA1c is increased by 11.26%、11.53%、10.31%、63.76%and43.95%with compared control group,and the differernces were significant(P<0.01).Serum PEDF levels were found to be comparable with the controls (P=0.584); (2) LDL and WC were positive correlation with PEDF (r=0.416, P<0.05; r=0.334, P<0.01).(3) PEDF levels was significant increased in type 2 diabetes after linagliptin the treatment (P<0.01),fasting glucose, HbA1C, weight, body mass index, LDL-C have different degrees of lower, the difference was significant.Conclusion:Serum PEDF level in patients with type 2 diabetes are similar to those of healthy controls, and associated with LDL, WC. After Linaglipin treatment serum PEDF level rise, suggest it may participate in the development of diabetes lipid metabolism. |
PDF Full Text Request